A surgeon in Michigan has performed the world’s first single-port robotic mitral valve repair.

TAVR can be especially challenging in patients with PAR and an enlarged LVOT. Specialists in China have developed a new technique that could improve outcomes for some of these patients without introducing new risks. 

Abbott's TriClip system for tricuspid regurgitation is approved by the FDA and covered by Medicare. To learn more about its real-world performance, researchers will now track 1,000 patients for a total of five years. 

Low-risk patients face comparable outcomes after TAVR and SAVR, researchers wrote, making it important to highlight even the smallest differences between these two approaches. 

In most cases, the issue should not cause harm. However, patients with a patent foramen ovale or other right-to-left shunts may face an increased risk of a heart attack or stroke.

Researchers are comparing the new-look Topaz TTVR system from TRiCares with the FDA-approved Evoque TTVR system from Edwards Lifesciences. 

The same device was previously recalled back in 2022. Customers are urged to return any unused delivery systems included in the recall to Medtronic.

TAVR continues to gain momentum as a go-to treatment option. A group of experts convened at CRT 2026 to discuss where the field stands today and what questions remain unanswered.